Overview

Acromegaly Combination Treatment Study

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily Pegvisomant will attain equivalent control of serum IGF-1 levels at a lower cost, compared to combination high dose SRL and weekly Pegvisomant. Lower doses of therapy will greatly reduce cost of acromegaly therapy.

Phase:

N/A

Details

Lead Sponsor:

Cedars-Sinai Medical Center

Treatments:

Angiopeptin
Lanreotide
Octreotide
Somatostatin